Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease.
Bowerman KL, Rehman SF, Vaughan A, Lachner N, Budden KF, Kim RY, Wood DLA, Gellatly SL, Shukla SD, Wood LG, Yang IA, Wark PA, Hugenholtz P, Hansbro PM. · 2020
Read Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. by Bowerman KL, Rehman SF, Vaughan A, Lachner N, Budden KF, Kim RY, Wood DLA, Gellatly SL, Shukla SD, Wood LG, Yang IA, Wark PA, Hugenholtz P, Hansbro PM. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7676259.txt.
Introduction
Bowerman and co-authors compare gut microbes in lung disease patients and healthy people. The disease is chronic obstructive pulmonary disease, a progressive lung illness with no cure. The lung microbe mix is known to matter, but the gut side was unclear.
Stool tests found 146 bacterial species that differed between patients and controls. Several species tracked with worse lung function. Chemical tests found a distinct patient signature, rich in lipid-related compounds. One microbe linked to a web of disease-tied chemicals. The authors say gut profiles may help in the search for markers of this disease.
Catalog record
| CREATOR | Bowerman KL, Rehman SF, Vaughan A, Lachner N, Budden KF, Kim RY, Wood DLA, Gellatly SL, Shukla SD, Wood LG, Yang IA, Wark PA, Hugenholtz P, Hansbro PM. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease By Kate L. Bowerman, Saima Firdous Rehman, Annalicia Vaughan, Nancy Lachner, Kurtis F. Budden, Richard Y. Kim, David L. A. Wood, Shaan L. Gellatly, Shakti D. Shukla, Lisa G. Wood, Ian A. Yang, Peter A. Wark Published in: Nature Communications DOI: 10.1038/s41467-020-19701-0 ABSTRACT Chronic obstructive pulmonary disease (COPD) is the third commonest cause of death globally, and manifests as a progressive inflammatory lung disease with no curative treatment. The lung microbiome contributes to COPD progression, but the function of the gut microbiome remains unclear. Here we examine the faecal microbiome and metabolome of COPD patients and healthy controls, finding 146 bacterial species differing between the two groups. Several species, including Streptococcus sp000187445, Streptococcus vestibularis and multiple members of the family Lachnospiraceae, also correlate with reduced lung function. Untargeted metabolomics identifies a COPD signature comprising 46% lipid, 20% xenobiotic and 20% amino acid related metabolites. Furthermore, we describe a disease-associated network connecting Streptococcus parasanguinis_B with COPD-associated metabolites, including N-acetylglutamate and its analogue N-carbamoylglutamate. While correlative, our results suggest that the faecal microbiome and metabolome of COPD patients are distinct from those of healthy individuals, and may thus aid in the search for biomarkers for COPD. INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with pulmonary pathologies, including chronic bronchitis, airway remodelling and emphysema that impair lung function. It has numerous systemic comorbidities such as cardiovascular disease, colitis and osteoporosis1,2. It is the third leading cause of death globally3, with the primary risk factor being the inhalation of cigarette smoke, air pollution or other noxious particles4,5. However, reportedly only 20–25% of smokers develop COPD6, and while some genetic risk factors have been described4, other factors such as inflammatory and immune responses are important in pathogenesis7. Current approaches to COPD therapy are limited and aim to manage symptoms and reduce exacerbations. High-dose-inhaled corticosteroids are widely employed, but their efficacy is limited to reducing exacerbation frequency or, combined with bronchodilators, improving COPD symptoms8. Many patients do not respond to steroid treatment7, and these therapies fail to modify the factors that initiate and drive disease progression, do not reverse tissue lesions or improve mortality and predispose to serious respiratory infection and pneumonia8,9. COPD is punctuated by exacerbations that worsen symptoms. Viruses and bacteria in the respiratory tract are associated with disease exacerbation; however, the heterogeneity of the disease and difficulties in sampling the lung make the exact nature of the relationship difficult to interpret10,11. Recently, the respiratory tract microbiome has emerged as a contributing factor in COPD progression outside of exacerbations with substantial overlap in identified viruses and bacteria during stable and exacerbated disease12. Comparison of sputum and bronchoalveolar lavage fluid (BALF) between stable COPD patients and healthy controls identified an increased abundance of Moraxella, Streptococcus, Veillonella, Eubacterium and Prevotella in disease13,14. However, other studies of BALF reported increased Prevotella enoeca but no difference in Streptococcus15. Comparisons of lung explants identified increased Proteobacteria and reduced Firmicutes and Bacteroidetes with decreased abundance of Streptococcus, Haemophilus influenza and Prevotella spp. in COPD16. Reduced bacterial diversity occurs in stable COPD patient sputum compared to healthy controls13; however, both increased and consistent diversity has been reported in BALF14,15. These studies suggest that the lung microbiome does not reproducibly change in COPD, which may be related to its transient nature produced by the balancing forces of immigration and elimination that typically impede long-term colonisation17,18. The co-morbidity of colitis suggests that the ‘gut-lung axis’ may be important in COPD pathogenesis19. Thus, we hypothesised that changes in the permanently colonised gut environment may contribute to pathogenesis and be a more reliable indicator of COPD. The concept of the gut–lung axis, describing the common mucosal immune system of the lung and gastrointestinal tract, implicates roles for the gut microbiome in regulating inflammation in acute and chronic respiratory disease including COPD18,19. Several studies implicate disturbances in the abundance or metabolism of gut bacteria in asthma and allergic airway disease20–22. In addition, the gut microbiome regulates host immune responses to respiratory infection19,23, and may, therefore, contribute to exacerbation frequency in COPD. COPD patients have increased incidence of gastrointestinal disturbances such as ulcerative colitis and Crohn’s disease and vice versa24,25, indicating potential roles for the gut microbiome in the disease. However, the gastrointestinal microbiome of COPD patients has not been assessed26,27. Here we compare the composition and functional potential of the gut microbiome in COPD patients with those of healthy controls, using untargeted faecal metagenomics and metabolomics. We describe an altered gut microbiome and metabolome associated with the disease. Several strepotococci and members of the family Lachnospiraceae discriminate between COPD patients and healthy controls in addition to correlating with impaired lung function. The metabolomic analysis identifies a shortlist of metabolites that may be potential biomarkers for validation in future studies. These findings support the gut microbiome and metabolome as being altered in association with COPD and highlight the need for further exploration of this environment to uncover whether it plays an active role in disease progression via the gut–lung axis. RESULTS Participant profiles We separately characterised the gut microbiome and metabolic profiles in COPD by analysing stool from individuals satisfying the global initiative for chronic obstructive lung disease (GOLD) criteria and healthy controls. A total of 28 COPD patients (54% female) and 29 healthy controls (66% female) were assessed, all during periods of stable disease (Supplementary Data 1). Information on GOLD status, dietary habits, smoking status and medication history was collected, along with spirometry and blood cell counts (Supplementary Data 1–5). COPD patients include four classified as GOLD I, 11 as GOLD II, eight as GOLD III and 11 as GOLD IV. The COPD cohort was older than healthy controls (mean age of 67 vs. 60, p = 0.012) and had a significantly higher proportion of past smokers (p = 0.005). Daily fibre intake was lower in COPD patients, while pulse rate, total white blood cell, neutrophil, monocyte and eosinophil counts were significantly higher. No significant differences were observed in body mass index (BMI), systolic or diastolic blood pressure, the proportion of current smokers, daily energy, carbohydrate, fat, protein, sugar or starch intake, haemoglobin, total red blood cell, platelet, lymphocyte or basophil counts between the groups (Supplementary Data 1). Faecal microbiome taxonomic indicators of COPD using 16S rRNA gene sequencing To compare the gut bacterial community composition between COPD patients and healthy individuals, we initially undertook 16S rRNA gene sequencing. In total, 4285 sequence variants were identified across all 57 faecal samples. After filtering for sequence variants present in at least two samples with a minimum relative abundance of 0.05%, 977 sequence variants were retained for community analysis. A significant difference in overall community composition was observed between COPD and healthy gut microbiomes (Fig. 1a, p < 0.0001 PERMANOVA of Bray–Curtis distances), without a significantly altered level of diversity (pShannon = 0.329, pSimpsonInverse = 0.291). COPD status explained 4% of the between-sample variability indicating substantial inter-individual differences that remained largely uncaptured by the addition of further demographic variables (Supplementary Data 6). Sequence variants contributing to the distinction between the groups were identified using multivariate sparse partial least-squares discriminant analysis (sPLS-DA, Fig. 1b–d, Supplementary Data 7). Genera increased in abundance in COPD